Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. WuXi AppTec Co., Ltd.
  6. News
  7. Summary
    603259   CNE1000031K4

WUXI APPTEC CO., LTD.

(603259)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

DMD: Charting the Path for New Therapeutics and Better Care

09/22/2021 | 01:22pm EST
Published On: 09.22.21
DMD: Charting the Path for New Therapeutics and Better Care
Featured

Dear colleagues and friends,

Thank you for participating in our global webinar, "Duchenne Muscular Dystrophy: Charting the Path for New Therapeutics and Better Care," which was co-organized with Parent Project Muscular Dystrophy (PPMD) and CureDuchenne. We are delighted that more than 1500 registered from 36 countries worldwide, coming together to raise awareness of this devastating rare disease, and to foster collaborations towards better medicines for patients.

For those who registered but couldn't make it, or who couldn't stay through the entire webinar, we have prepared a replay link. Please click HERE to watch the on-demand video.

At WuXi AppTec, we firmly believe in a future where "every drug can be made and every disease can be treated". That future is only possible if we all work together.

Thank you again, and we hope to see you at our next episode of WuXi AppTec Rare Disease webinar series.

Disclaimer

WuXi AppTec Co. Ltd. published this content on 22 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 September 2021 17:21:08 UTC.


© Publicnow 2021
All news about WUXI APPTEC CO., LTD.
11/15WUXI APPTEC : ATU Opens New Facility in Philadelphia, Tripling Testing Capacity to Support..
PU
11/08Hoth Therapeutics, Inc. Inks API and Drug Product Contracts with STA Pharmaceutical to ..
CI
11/01WuXi Apptec's Q3 Profit Jumps 36.2% on Higher Capacity Utilization; Hong Kong Shares Dr..
MT
10/29WuXi AppTec Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, ..
CI
10/29WuXi AppTec Reports Strong Third-Quarter 2021 Results
PU
10/29WuXi AppTec Third Quarter 2021 Earnings Presentation
PU
10/292021 third quarterly
PU
10/17WUXI APPTEC : ATU Opens New Manufacturing Facility to Further Enhance Its CTDMO Services f..
PU
10/06SIRONA BIOCHEM : On Advancement of TFC-1067 Compound
MT
09/22DMD : Charting the Path for New Therapeutics and Better Care
PU
More news
Analyst Recommendations on WUXI APPTEC CO., LTD.
More recommendations
Financials
Sales 2021 22 633 M 3 551 M 3 551 M
Net income 2021 4 574 M 718 M 718 M
Net cash 2021 8 343 M 1 309 M 1 309 M
P/E ratio 2021 97,7x
Yield 2021 0,28%
Capitalization 418 B 65 580 M 65 520 M
EV / Sales 2021 18,1x
EV / Sales 2022 13,7x
Nbr of Employees 33 305
Free-Float 58,3%
Chart WUXI APPTEC CO., LTD.
Duration : Period :
WuXi AppTec Co., Ltd. Technical Analysis Chart | 603259 | CNE1000031K4 | MarketScreener
Technical analysis trends WUXI APPTEC CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 146,32 CNY
Average target price 184,32 CNY
Spread / Average Target 26,0%
EPS Revisions
Managers and Directors
Min Zhang Chen Co-Chief Executive Officer
Qing Yang Co-CEO, Executive Director & Executive VP
Ge Li Chairman & President
Ellis Chu Chief Financial Officer & Senior Vice President
Harry He Chairman-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
WUXI APPTEC CO., LTD.30.33%67 780
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE310.30%80 784
REGENERON PHARMACEUTICALS31.76%65 932
VERTEX PHARMACEUTICALS-13.26%52 122
BEIGENE, LTD.36.22%32 911